Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+peptides

30 Results Sort By:
Cell-Permeable Protein Therapeutic for Pain and Itch
Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...
Published: 5/9/2024   |   Inventor(s): Hao-Jui Weng, Xinzhong Dong
Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain
Chemokine-derived Peptides that Induce Immunogenic Cancer Cell Death
Value PropositionHigh cancer cell specificity by cell surface characteristics.High water solubility.Combination of oncolytic and anti-angiogenic properties.Unmet NeedThere currently are no peptides reported to have both oncolytic and anti-angiogenic activities. Additionally, drug development requires solubility in water; however, the reported oncolytic...
Published: 5/10/2024   |   Inventor(s): Aleksander Popel, Natsuki Furukawa, Niranjan Pandey, Adam Mirando
Keywords(s):  
Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Peptides, Technology Classifications > Therapeutic Modalities > Peptides
Compositions of Kinetic Nanoparticles containing Nucleic Acids, Polycations, and Lipids with Defined Sizes, and Methods of Producing the Same
Value Proposition:·        Scalable, efficient, and tunable nanoparticle creation technique that can deliver a variety of payloads·        Polymer-lipid nanoparticles are biodegradable and are being tested for immunogenicity·        Can be used for in vivo gene therapy delivery as well as in vitro cell transfection and research applications Technology...
Published: 5/10/2024   |   Inventor(s): Hai-Quan Mao, Stephany Tzeng, Jordan Green, Yizong Hu, Sashank Reddy, Leonardo Cheng
Keywords(s):  
Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology, Technology Classifications > Engineering Tech > Materials, Technology Classifications > Research Tools > Nucleic Acids, Technology Classifications > Research Tools > Peptides, Technology Classifications > Research Tools > Vectors & Plasmids, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
Peptide for the Prevention and Treatment of Coronavirus Infection
Value Proposition·        Peptide-based supramolecular filament that attenuates SARS-CoV virus infectivity in vivo·        Leverages ACE2 enzyme-substrate docking activity·        Enables therapeutic protein delivery in repairable aerosolsUnmet Need·        Respiratory illnesses, including tuberculosis, influenza, and COVID-19, pose a significant worldwide...
Published: 5/10/2024   |   Inventor(s): Honggang Cui, Hongpeng Jia, Caleb Anderson
Keywords(s):  
Category(s): Clinical and Disease Specializations > Respiratory Diseases, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
Nanoparticle-NHE3 Peptide to Treat Diarrhea
Value Proposition:·        Nanoparticle-based delivery of therapeutic that enhances intestinal sodium absorption ·        Broad clinical applications in severe diarrhea, whether acute or chronic·        Effective treatment across heterogeneous presentations of diarrhea ·        Appropriate for patients of all ages Technology Description·        Researchers...
Published: 5/10/2024   |   Inventor(s): Mark Donowitz, Jordan Green, Nicholas Zachos, Hannah Vaughan
Keywords(s):  
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology > Crohn's Disease, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Clinical and Disease Specializations > Gastroenterology > Ulcerative Colitis, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
KRAS Inhibitor
KRAS Oncogene InhibitorJHU Ref #: C16567Value Proposition·        KRAS oncogene function inhibitor·        24 amino acid peptide synthesized from KRAS4B structure·        Enables development of KRAS-driven cancer therapeuticsUnmet NeedKRAS is an oncoprotein involved in cell division regulation with gene mutations leading to cellular transformations...
Published: 5/10/2024   |   Inventor(s): Miho Iijima, Hiroshi Senoo, Hiromi Sesaki
Keywords(s):  
Category(s): Technology Classifications > Research Tools > Peptides, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Oncology
Radiolabeled Thapsigargin Analogs Incorporated into Protease Activated Prodrugs
Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific membrane antigen (PSMA), prostate specific antigen (PSA) or human glandular kallikrein 2 (hK2). Various embodiments relate more specifically to PSA, hK2 or PSMA-specific peptide prodrugs that become...
Published: 5/9/2024   |   Inventor(s): Soren Christensen, John Isaacs, Samuel Denmeade
Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer
Human Serum Albumin-PSA proaerolysin Prodrug
UNMET NEEDThe current standards of care for prostate cancer (Pca) include hormonal therapy, radiation therapy, surgery, chemotherapy, and combinational therapy. However, these treatments often have side effects that affect the quality of life of the Pca patients. Hence, there is an urgent need for developing better target-based therapies. This technology...
Published: 5/9/2024   |   Inventor(s): John Isaacs, Samuel Denmeade, William Brennen
Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Prostate Cancer, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer
Compositions and Method for Production of Size-Controlled Ternary Nanoparticles for Sustained Release of Peptide Therapeutics
Unmet NeedType 2 diabetes (T2D) contributes to 90% of all cases of diabetes and represents a critical global public health problem. T2D specifically affects glucose metabolism and those with the disease either do not produce enough insulin or do not respond properly to insulin signaling to maintain normal levels of glucose in the blood. Several serious...
Published: 5/9/2024   |   Inventor(s): Hai-Quan Mao, Zhiyu He, Yizong Hu, Yongming Chen, Lixin Liu
Keywords(s): Biologics, Drug Delivery Vehicle, Drug Delivery Vehicle Synthesis Method, Nanoparticles, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers
HIF-1
The purified and characterization of hypoxia-inducible factor 1 (HIF-1) is described. HIF-1 is composed of subunits HIF-1 and HIF-1 . Purified HIF-1 polypeptide, its amino acid sequence and polynucleotide sequence are provided. A HIF-1 variant that dimerizes to HIF-1 producing a nonfunctional HIF-1 complex is described. Methods for the prevention and...
Published: 5/9/2024   |   Inventor(s): Gregg Semenza
Keywords(s): Biologics, Cardiovascular Diseases, Disease Indication, Polypeptide, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides
1 2 3 
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum